Denmark-based Curasight has dosed the first patient in the Phase I clinical trial of its uTREAT diagnostic platform, targeting high-grade gliomas.

The trial marks the company’s initial clinical study investigating this platform as a potential therapy for glioblastoma (GBM), an aggressive brain cancer.

With this Phase I trial, Curasight now has uTRACE and uTREAT in the clinical phase, aiming to advance the diagnosis and treatment of specific cancers.

The study is designed to assess uTREAT as a targeted radiopharmaceutical therapy in patients newly diagnosed with, or suspected of having GBM.

Its design is based on previous research and studies with uTRACE, as well as protocol discussions with key opinion leaders in the field.

Curasight’s uTRACE and uTREAT target the urokinase-type plasminogen activator receptor (uPAR).

The uPAR theranostic platform integrates uTRACE's diagnostic capabilities, which deliver sensitive imaging, with the therapeutic potential of uTREAT, which provides targeted radiopharmaceutical treatment.

Both technologies are designed to offer a combined approach to managing cancers that express uPAR.

Curasight CEO Ulrich Krasilnikoff said: “The dosing of the first patient with uTREAT in this Phase I trial marks an important step in the development of the therapeutic arm of our theranostic platform, making Curasight a clinical-stage therapeutic company. 

“I very much look forward to seeing the data and would like to take this opportunity to thank the patient and doctors involved in this trial in supporting our efforts to develop uTREAT."

Curasight’s uTRACE is currently in a Phase II clinical trial for prostate cancer, in collaboration with Curium.

In May 2023, Curasight and Curium agreed to develop and commercialise the uTRACE positron emission tomography imaging technology for use in prostate cancer.